eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Clinical trial NCT02767804 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02767804
- Sponsor
- Xcovery Holdings, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2025-12-30
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.